Dexcom's OTC Glucose Monitor Reaches Type 2 Diabetics Without Prescription

Dexcom's Stelo continuous glucose monitor became available without prescription in August 2024, after FDA approval. Unlike traditional CGM devices, Stelo targets type 2 diabetics who don't require insulin—a significantly larger population than prescription-based models serve. The move marks a regulatory shift that expands real-time glucose tracking beyond medical-grade disease management into consumer health awareness, changing addressable market economics for established diabetes device makers.